This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Discovery Corporation Responds To Tabloid “News”

Health Discovery Corporation (OTCBB: HDVY) would like to respond to a tabloid story that appeared this past week about the Company that contained a number of untruths. It is worth noting that it appears that Health Discovery Corporation is caught in ongoing crossfire between two competing stock market news services, one that recently issued an independent, positive report on the Company that was, in turn, followed by the tabloid story last week.

The Company points out the following:
  • The Company takes very seriously its contractual obligations, including confidentiality provisions. As a result, the Company is required under contract law to limit the amount of information it can provide the public, including journalists. We make no apologies for adhering to our contractual obligations.
  • The Company stands by the superior sensitivity and specificity of our new, non-invasive, four-gene prostate cancer test published in the peer-reviewed publication, UroToday, in August, 2009. The Company stands by its public disclosures related to this test and is pleased with its continued progress.

Here are some independent commentaries on the PSA:

Dr. Otis Brawley, the chief medical officer of the American Cancer Society, and quoted in last week’s tabloid attack on Health Discovery Corporation, had this to say about the PSA: “The PSA test is about 50 times more likely to ruin your life than it is to save your life.”

The New England Journal of Medicine published in March 2009 the results of the largest prostate cancer studies in the U.S. and Europe, which said: “We now know that prostate-cancer screening (PSA) provided no reduction in the death rates at 7 years and that no indication of a benefit appeared with 67% of the subjects having completed 10 years of follow-up.”

“The rate of overdiagnosis of prostate cancer has been estimated to be as high as 50% in the (PSA) screening group… Overdiagnosis and overtreatment are probably the most important adverse effects of prostate-cancer screening and are vastly more common than in screening for breast, colorectal, or cervical cancer.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HDVY $0.03 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs